Procopio et al., 2014 - Google Patents
Sorafenib as first-or second-line therapy in patients with metastatic renal cell carcinoma in a community settingProcopio et al., 2014
View PDF- Document ID
- 18024268221395044037
- Author
- Procopio G
- Derosa L
- Gernone A
- Morelli F
- Sava T
- Zustovich F
- De Giorgi U
- Ferrari V
- Sabbatini R
- Gasparro D
- Felici A
- Burattini L
- Calvani N
- Lo Re G
- Banna G
- Pia Brizzi M
- Rizzo M
- Ciuffreda L
- Iacovelli R
- Ferrau F
- Taibi E
- Bracarda S
- Porta C
- Galligioni E
- Contu A
- Publication year
- Publication venue
- Future Oncology
External Links
Snippet
ABSTRACT Aim: The Italian Retrospective Analysis of Sorafenib as First or Second Target Therapy study assessed the efficacy and safety of sorafenib in metastatic renal cell carcinoma patients treated in the community. Patients & methods: Patients receiving first-or …
- 239000005511 L01XE05 - Sorafenib 0 title abstract description 114
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Marra et al. | Are all cyclin-dependent kinases 4/6 inhibitors created equal? | |
Nagasaka et al. | Role of chemotherapy and targeted therapy in early-stage non-small cell lung cancer | |
Neal et al. | Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial | |
Iacovelli et al. | Targeted therapies and complete responses in first line treatment of metastatic renal cell carcinoma. A meta-analysis of published trials | |
Solit et al. | Towards a unified model of RAF inhibitor resistance | |
Gadaleta-Caldarola et al. | Sorafenib: 10 years after the first pivotal trial | |
Jäger et al. | Sorafenib treatment of advanced renal cell carcinoma patients in daily practice: the large international PREDICT study | |
Liu et al. | A randomized Phase II clinical study of combining panitumumab and bevacizumab, plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) compared with FOLFIRI alone as second-line treatment for patients with metastatic colorectal cancer and KRAS mutation | |
Di Lorenzo et al. | An adjusted indirect comparison of everolimus and sorafenib therapy in sunitinib-refractory metastatic renal cell carcinoma patients using repeated matched samples | |
Inomata et al. | Continuous administration of EGFR-TKIs following radiotherapy after disease progression in bone lesions for non-small cell lung cancer | |
Agwa et al. | Targeting the MET receptor tyrosine kinase in non-small cell lung cancer: emerging role of tivantinib | |
Abdel-Rahman et al. | Risk of cardiovascular toxicities in patients with solid tumors treated with sorafenib: an updated systematic review and meta-analysis | |
Procopio et al. | Sorafenib as first-or second-line therapy in patients with metastatic renal cell carcinoma in a community setting | |
Garg et al. | Exposure–response analysis of pertuzumab in HER2-positive metastatic breast cancer: absence of effect on QTc prolongation and other ECG parameters | |
Yuan et al. | Critical appraisal of the role of gefitinib in the management of locally advanced or metastatic non-small cell lung cancer | |
Zeng et al. | Apatinib in the treatment of advanced lung adenocarcinoma with KRAS mutation | |
Abdel-Rahman et al. | Risk of mucocutaneous toxicities in patients with solid tumors treated with sunitinib: a critical review and meta analysis | |
Vavalà | Role of afatinib in the treatment of advanced lung squamous cell carcinoma | |
Procopio et al. | Targeted therapies used sequentially in metastatic renal cell cancer: overall results from a large experience | |
Areethamsirikul et al. | The risk of secondary primary malignancies after therapy for multiple myeloma | |
Paglino et al. | Sunitinib in advanced metastatic non-clear cell renal cell carcinoma: a single institution retrospective study | |
Bersanelli et al. | Immune checkpoint inhibitors in non-conventional histologies of renal-cell carcinoma | |
Antoun et al. | Clinical implications of body composition assessment by computed tomography in metastatic renal cell carcinoma | |
Worley | Lung cancer research is taking on new challenges: knowledge of tumors’ molecular diversity is opening new pathways to treatment | |
Abdel-Rahman et al. | Risk of fatigue and hepatic and metabolic toxicities in patients with solid tumors treated with everolimus: a meta-analysis |